This article discusses the Supreme Court's decision that colleges and universities may no longer consider race as part of the college admissions process, and the future effects it could have for private employers and corporate DEI initiatives.
This article discusses the ruling by a California Court of Appeal that ultimately determined a hospital's decision to terminate an employee for failing to comply with its flu vaccine mandate did not violate California's Fair Employment and Housing Act (FEHA).
This article discusses the Department of Labor's October 2022 notice of proposed rulemaking (“NPRM”) defining employee versus independent contractor status under the Fair Labor Standards Act.
This article discusses The Pregnant Workers Fairness Act (“PWFA”) which creates new rights to reasonable accommodation for employees and applicants who have physical or mental conditions arising from pregnancy, childbirth or related medical conditions. The PWFA expands accommodation rights for pregnant individuals to be more in line with -- and in some respects, more expansive than -- those provided to qualified individuals with disabilities under the Americans with Disabilities Act (ADA).
This article discusses the Equal Employment Opportunity Commission's May 2023 guidance on advanced technologies in the workplace. The guidance does not unveil new policies, but instead reiterates that existing policies and practices continue to apply to new technologies.
In this multi-jurisdictional guide, explore an overview of key legal issues, rules and developments regarding corporate immigration across a range of jurisdictions.
Some topics discussed include a global overview of modern slavery and corporate supply chain compliance and more.
This article discusses the National Labor Relations Board (NLRB) General Counsel's memorandum explaining that noncompete agreements in employment contracts and severance agreements violate the National Labor Relations Act (NLRA) except in limited circumstances.
This article discusses the critical decisions that are pending before courts and legislators in 2023 that promise to shape the future of the 340B Drug Pricing Program (340B Program), which provides discounts on outpatient drugs for certain health care providers, referred to as “covered entities.” The resolution of these issues will have an enormous financial impact on the health care industry, including pharmaceutical manufacturers, 340B hospitals, and federal grantees.
This blog focuses on U.S. Food and Drug Administration (FDA) published framework to guide regulatory decision-making on the use of digital health technologies (DHT) in clinical drug trials. DHTs include a wide array of technologies, including software applications that run on a phone, wearables, and environmental sensors, among others. As DHT becomes more sophisticated, the technologies have the potential to play an even larger role in health care, including clinical research.
This blog explores the U.S. Food & Drug Administration (FDA) two final guidance documents to assist with transitioning medical devices: (i) that were subject to certain enforcement policies issued during the COVID-19 Public Health Emergency (PHE), and (ii) that were issued emergency use authorizations (EUAs). These guidance documents finalize the corresponding draft guidance documents that were issued on December 23, 2021.